Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Blood Rev. 2019 Nov 2;40:100636. doi: 10.1016/j.blre.2019.100636

Table 4-.

Studies that evaluate the role of induction treatment before ASCT in AL amyloidosis.

The study Number of patients Treatment arms Cardiac involvement % Hematological response % TRM % Median PFS/OS Comments
Scott 2014 56 2 Vd Vs no induction 48 Higher CR in the induction arm 9.6 3yOS 73% Retrospective trial. The median time to maximum hematologic response after ASCT was reduced in the induction arm (3 vs. 14 months).
Sanchorawala 2004 100 2 MP Vs No induction 46 Not different between the groups NR Not different between the groups Prospective trial.
Afrough 2018 128 MP (25 pt) vs Novel agent (83 pt) Vs no induction (20 pt) 29 HR at 100 d 62% in MP arm 87% in novel agent arm and 60% in no induction arm NR 2y PFS not different between the groups. 2y OS were 76% in MP, 87% in novel agent arm and 73% in no induction Retrospective

Novel agents = thalidomide, lenalidomide, or bortezomib